Stockscreener 앱 받기
1.67
7.18%
-0.14
시간 외 거래:
1.67
Palisade Bio Inc 주식(PALI)의 최신 뉴스
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Palisade Bio, Inc. (NASDAQ:PALI) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
MACD Signal: Does Palisade Bio Inc have declining or rising EPSWeekly Profit Recap & Risk Managed Investment Strategies - baoquankhu1.vn
Portfolio Update: Is CINGW a potential multi baggerInflation Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Palisade Bio, Inc. (NASDAQ:PALI) Short Interest Up 24.4% in December - MarketBeat
Published on: 2026-01-19 10:30:24 - baoquankhu1.vn
Aug Retail: Should I invest in Palisade Bio Inc before earningsInsider Selling & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Activity Recap: Can Palisade Bio Inc beat the S P 500Weekly Profit Summary & AI Based Buy and Sell Signals - baoquankhu1.vn
Palisade Bio announces two abstracts selected for poster presentations at leading global inflammatory bowel disease conferences - marketscreener.com
Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences - Weekly Voice
Palisade Bio (PALI) Price Target Increased by 12.86% to 13.43 - Nasdaq
Palisade Bio director Williams buys $9,400 in shares By Investing.com - Investing.com South Africa
Palisade Bio director Williams buys $9,400 in shares - Investing.com
Sentiment Watch: Can Palisade Bio Inc beat the S P 500July 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B. Riley Initiates Palisade Bio at Buy With $7 Price Target - marketscreener.com
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com UK
B.Riley initiates coverage on Palisade Bio stock with Buy rating By Investing.com - Investing.com India
How Palisade Bio Inc. (7NS0) stock reacts to Fed tighteningShort Setup & Consistent Profit Trading Strategies - Улправда
Can Palisade Bio Inc. stock deliver consistent earnings growthTrade Risk Report & Expert Approved Momentum Ideas - Улправда
What is the fair value of Palisade Bio Inc. stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - ulpravda.ru
Crohn’s & Colitis Foundation invests up to $500,000 in Palisade Bio By Investing.com - Investing.com Nigeria
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда
Exit Recap: Will Palisade Bio Inc stock attract more institutional investors2025 AllTime Highs & High Conviction Buy Zone Alerts - Bộ Nội Vụ
Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108 - The Manila Times
Palisade Bio Announces Strategic Equity Investment from the - GlobeNewswire
Crohn’s & Colitis Foundation backs new gut-targeted drug for severe IBD - Stock Titan
Will Palisade Bio Inc. stock benefit from sector rotationStability vs Neutral Overview & HOKA buying tips before checkout - ulpravda.ru
Palisade Bio, Inc. (NASDAQ:PALI) Receives $20.50 Average Price Target from Analysts - Defense World
Wall Street Zen Upgrades Palisade Bio (NASDAQ:PALI) to "Hold" - MarketBeat
Risk Report: What is the fair value of Palisade Bio Inc stock now2025 Major Catalysts & Intraday High Probability Setup Alerts - moha.gov.vn
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Clear Str - MarketBeat
Piper Sandler Initiates Coverage on Palisade Bio (NASDAQ:PALI) - Defense World
9,119,152 Common Stock of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Stock Options of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Warrants of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 - Investing.com Nigeria
Palisade Bio Says Japan Grants Patent for Composition of PALI-2108 - MarketScreener
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 By Investing.com - Investing.com South Africa
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
Palisade Bio (NASDAQ:PALI) Upgraded at Piper Sandler - MarketBeat
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 - The Manila Times
2.45%
4.02%
자본화:
|
볼륨(24시간):